Detail akcie Supernus online

Business Summary: Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Supernus Pharmaceuticals Inc revenues increased 4% to $507.4M. Net loss totaled $34.4M vs. income of $58.5M. Revenues reflect Net product sales-Qelbree segment increase of 34% to $223.7M, Other segment increase from $7.2M to $22.1M, Net product sales - GOCOVRI segment increase of 15% to $108.2M, United States segment increase of 47% to $507.4M.